【24h】

Peroxisome proliferator-activated receptor alpha and hypertensive heart disease.

机译:过氧化物酶体增殖物激活受体α和高血压心脏病。

获取原文
获取原文并翻译 | 示例
           

摘要

Peroxisome proliferator-activated receptor alpha (PPARalpha) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. It is expressed by cardiomyocytes and regulates gene expression of key proteins involved in myocardial lipid and energy metabolism. Accordingly, the activitity of PPARalpha is an important determinant of cardiomyocyte lipid homeostasis and ATP production. Currently, animal and human data suggest that deactivation of PPARalpha may contribute substantially to phenotypic changes that accompany cardiac growth in conditions of pressure overload, and the hypothesis emerges that a compromised PPARalpha activity may participate in the transition from compensated left ventricular hypertrophy to heart failure in hypertensive heart disease. The availability of PPARalpha activators (e.g. fibric acid derivates and statins) must stimulate investigation into the potential cardioprotective actions of these compounds beyond their hypolipidaemic effects and via restoration of PPARalpha activity in the hypertrophied and failing heart.
机译:过氧化物酶体增殖物激活受体α(PPARalpha)是属于核激素受体超家族的配体激活转录因子。它由心肌细胞表达并调节参与心肌脂质和能量代谢的关键蛋白的基因表达。因此,PPARalpha的活性是心肌脂质稳态和ATP产生的重要决定因素。目前,动物和人类的数据表明,PPARα的失活可能在压力超负荷的情况下大大促进伴随心脏生长的表型变化,并且假说表明,受损的PPARα活性可能参与了从补偿性左心室肥大到心力衰竭的转变。高血压心脏病。 PPARalpha激活剂(例如,纤维酸衍生物和他汀类药物)的可用性必须激发人们对这些化合物潜在的心脏保护作用的研究,超越其降血脂作用,并通过恢复肥大和衰竭心脏中的PPARalpha活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号